Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CD19-targeted 4-1BB ligand RO7227166

An immunotherapeutic agent that targets both CD19 and 4-1BB (CDG5:I9necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulatory and antineoplastic activity. Upon administration, CD19-targeted 4-1BB ligand RO7227166 simultaneously binds to CD19 and 4-1BB, thereby crosslinking CD19 and 4-1BB positive cells. This triggers, through the 4-1BB ligand, the proliferation and activation of natural killer cells (NKs) and T cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against CD19-expressing tumor cells. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily (TNFRSF), is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:CD19-4-1BBL RO7227166
Code name:RO 7227166
RO-7227166
RO7227166
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search